Serendipitous COVID-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity Assessment of a Heterologous Regime
Preprint
Abstract
Immunization program against COVID-19 in India started with two vaccines; AstraZeneca’s ChAdOx1-nCov-19 (termed Covishield in India) and inactivated whole virion BBV152 (Covaxin); homologous prime-boost approach was followed. However, eighteen individuals, under the national program, inadvertently received Covishield as the first jab and Covaxin as the second. We compared the safety and immunogenicity profile of them against that of individuals receiving either Covishield or Covaxin (n=40 in each group). Lower and similar adverse events following immunization in all three groups underlined the safety of the combination vaccine-regime. Immunogenicity profile against Alpha, Beta and Delta variants in heterologous group was superior; IgG antibody and neutralising antibody response of the participants was also significantly higher compared to that in the homologous groups. The findings suggest that immunization with a combination of an adenovirus vector platform-based vaccine followed by an inactivated whole virus vaccine was not only safe but also elicited better immunogenicity.Keywords
This publication has 18 references indexed in Scilit:
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialThe Lancet Infectious Diseases, 2021
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trialThe Lancet Infectious Diseases, 2021
- India’s role in COVID-19 vaccine diplomacyJournal of Travel Medicine, 2021
- The world's largest COVID-19 vaccination campaignThe Lancet Infectious Diseases, 2021
- Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidatesEmerging Microbes & Infections, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesNature Medicine, 2020
- Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patientsIndian Journal of Medical Research, 2020
- Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgGIndian Journal of Medical Research, 2020
- Full-genome sequences of the first two SARS-CoV-2 viruses from IndiaIndian Journal of Medical Research, 2020